MetLife Investment Management LLC Has $5.24 Million Holdings in Encompass Health Co. (NYSE:EHC)

MetLife Investment Management LLC lifted its holdings in Encompass Health Co. (NYSE:EHC - Free Report) by 9.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 56,762 shares of the company's stock after acquiring an additional 4,784 shares during the quarter. MetLife Investment Management LLC owned approximately 0.06% of Encompass Health worth $5,242,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Norges Bank acquired a new position in Encompass Health in the fourth quarter worth $100,637,000. Raymond James Financial Inc. bought a new position in shares of Encompass Health in the fourth quarter valued at about $77,944,000. Jennison Associates LLC acquired a new position in Encompass Health during the 4th quarter worth about $52,094,000. abrdn plc bought a new stake in Encompass Health during the 4th quarter worth about $17,846,000. Finally, Invesco Ltd. increased its position in Encompass Health by 3.3% in the 4th quarter. Invesco Ltd. now owns 5,536,251 shares of the company's stock valued at $511,273,000 after acquiring an additional 176,135 shares in the last quarter. 97.25% of the stock is currently owned by institutional investors.

Insider Activity

In other Encompass Health news, CAO Andrew L. Price sold 5,042 shares of Encompass Health stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $98.29, for a total transaction of $495,578.18. Following the transaction, the chief accounting officer now directly owns 69,164 shares in the company, valued at approximately $6,798,129.56. The trade was a 6.79 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 2.10% of the stock is owned by company insiders.

Encompass Health Trading Up 0.1 %

Shares of Encompass Health stock traded up $0.08 during trading on Tuesday, reaching $115.40. 293,450 shares of the company were exchanged, compared to its average volume of 676,522. Encompass Health Co. has a twelve month low of $82.38 and a twelve month high of $116.20. The business has a 50-day moving average price of $100.35 and a 200-day moving average price of $98.71. The company has a quick ratio of 1.04, a current ratio of 1.05 and a debt-to-equity ratio of 0.84. The firm has a market capitalization of $11.62 billion, a price-to-earnings ratio of 25.86, a P/E/G ratio of 2.31 and a beta of 0.87.

Encompass Health (NYSE:EHC - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The company reported $1.37 EPS for the quarter, beating analysts' consensus estimates of $1.19 by $0.18. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. The company had revenue of $1.46 billion during the quarter, compared to analysts' expectations of $1.43 billion. During the same period in the prior year, the business posted $1.12 EPS. Encompass Health's revenue was up 10.6% on a year-over-year basis. Sell-side analysts anticipate that Encompass Health Co. will post 4.8 EPS for the current fiscal year.

Encompass Health Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Tuesday, April 1st were given a dividend of $0.17 per share. The ex-dividend date of this dividend was Tuesday, April 1st. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.59%. Encompass Health's dividend payout ratio is 14.05%.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on EHC. Royal Bank of Canada upped their target price on shares of Encompass Health from $110.00 to $125.00 and gave the stock an "outperform" rating in a research report on Monday. UBS Group increased their price objective on Encompass Health from $117.00 to $130.00 and gave the company a "buy" rating in a research report on Monday. Truist Financial restated a "buy" rating and set a $135.00 target price (up previously from $116.00) on shares of Encompass Health in a research report on Monday. KeyCorp upped their price target on Encompass Health from $120.00 to $122.00 and gave the company an "overweight" rating in a research note on Friday. Finally, Barclays lifted their price objective on Encompass Health from $118.00 to $129.00 and gave the stock an "overweight" rating in a research report on Friday. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $120.86.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.